甲状腺眼病-话题@MedSci

#甲状腺眼病#

7篇内容 | 802人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2148712, encodeId=36f52148e1222, content=<a href='/topic/show?id=469410644505' target=_blank style='color:#2F92EE;'>#FcRn抑制剂#</a><a href='/topic/show?id=1d4b106446ae' target=_blank style='color:#2F92EE;'>#batoclimab#</a>在<a href='/topic/show?id=9a0982481a' target=_blank style='color:#2F92EE;'>#Graves病#</a>和相关的<a href='/topic/show?id=55f5699017b' target=_blank style='color:#2F92EE;'>#甲状腺眼病#</a>(ted)的<a href='/topic/show?id=973f10134117' target=_blank style='color:#2F92EE;'>#首次临床研究#</a>，<a href='/topic/show?id=cb7c10644e43' target=_blank style='color:#2F92EE;'>#概念验证#</a>POC就采用<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>，看来研究真的太卷了！！这也提示<a href='/topic/show?id=65c858648d2' target=_blank style='color:#2F92EE;'>#新药研发#</a>的要求越来越高！！难度越来越大！, objectTitle=J Clin Endocrinol Metab：FcRN抑制剂BATOCLIMAB治疗甲状腺眼病的概念验证和随机安慰剂对照试验, objectType=article, longId=781528, objectId=6183e8152848, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230712/1689168746988_2480734.jpg, objectUrl=/article/show_article.do?id=6183e8152848, replyNumber=0, likeNumber=48, createdTime=2023-07-19, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=加利福尼亚, moduleDTOList=[ModuleDTO(moduleId=6183e8152848, moduleTitle=J Clin Endocrinol Metab：FcRN抑制剂BATOCLIMAB治疗甲状腺眼病的概念验证和随机安慰剂对照试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6183e8152848)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=2023973, encodeId=2c0e20239e383, content=<a href='/topic/show?id=55f5699017b' target=_blank style='color:#2F92EE;'>#甲状腺眼病#</a>, objectTitle=2019美国甲状腺学会ATA：临床试验证实Teprotumumab可显着改善甲状腺眼病的眼胀、复视和炎症, objectType=article, longId=182365, objectId=732918236572, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=732918236572, replyNumber=0, likeNumber=43, createdTime=2020-01-23, rootId=0, userName=qidongfanjian, userId=b09892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=732918236572, moduleTitle=2019美国甲状腺学会ATA：临床试验证实Teprotumumab可显着改善甲状腺眼病的眼胀、复视和炎症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=732918236572)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2023972, encodeId=265d20239e266, content=<a href='/topic/show?id=55f5699017b' target=_blank style='color:#2F92EE;'>#甲状腺眼病#</a>, objectTitle=2019年美国临床内分泌学家协会（AACE）大会：Teprotumumab治疗甲状腺眼病的III期试验结果, objectType=article, longId=164221, objectId=3dc6164221e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dc6164221e6, replyNumber=0, likeNumber=60, createdTime=2019-05-24, rootId=0, userName=qidongfanjian, userId=b09892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dc6164221e6, moduleTitle=2019年美国临床内分泌学家协会（AACE）大会：Teprotumumab治疗甲状腺眼病的III期试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dc6164221e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2023971, encodeId=b70e20239e152, content=<a href='/topic/show?id=55f5699017b' target=_blank style='color:#2F92EE;'>#甲状腺眼病#</a>, objectTitle=Horizon的teprotumumab治疗活动性甲状腺眼病III期临床试验大获成功, objectType=article, longId=161504, objectId=8f841615044d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f841615044d, replyNumber=0, likeNumber=33, createdTime=2019-06-27, rootId=0, userName=qidongfanjian, userId=b09892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f841615044d, moduleTitle=Horizon的teprotumumab治疗活动性甲状腺眼病III期临床试验大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f841615044d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2023970, encodeId=709220239e0bb, content=<a href='/topic/show?id=55f5699017b' target=_blank style='color:#2F92EE;'>#甲状腺眼病#</a>, objectTitle=Ophthalmic Plast Reconstr Surg：上直肌-提肌复合体的增大对甲状腺眼病等压迫性视神经病变有显着贡献, objectType=article, longId=147328, objectId=f3b014e32814, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3b014e32814, replyNumber=0, likeNumber=47, createdTime=2018-09-01, rootId=0, userName=qidongfanjian, userId=b09892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3b014e32814, moduleTitle=Ophthalmic Plast Reconstr Surg：上直肌-提肌复合体的增大对甲状腺眼病等压迫性视神经病变有显着贡献, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3b014e32814)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2023968, encodeId=89ce2023968b0, content=<a href='/topic/show?id=55f5699017b' target=_blank style='color:#2F92EE;'>#甲状腺眼病#</a>, objectTitle=Ophthalmic Plast Reconstr Surg：从解剖学角度看甲状腺眼病, objectType=article, longId=140773, objectId=8c6f140e73bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c6f140e73bd, replyNumber=0, likeNumber=51, createdTime=2018-07-08, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c6f140e73bd, moduleTitle=Ophthalmic Plast Reconstr Surg：从解剖学角度看甲状腺眼病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c6f140e73bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2023969, encodeId=a55b202396907, content=<a href='/topic/show?id=55f5699017b' target=_blank style='color:#2F92EE;'>#甲状腺眼病#</a>, objectTitle=Curr Opin Ophthalmol：甲状腺眼病的研究进展, objectType=article, longId=147327, objectId=d70f14e327a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d70f14e327a0, replyNumber=0, likeNumber=43, createdTime=2018-12-24, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d70f14e327a0, moduleTitle=Curr Opin Ophthalmol：甲状腺眼病的研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d70f14e327a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

甲状腺眼病

2020-05-29

(审核中...)

前往app查看评论内容

#FcRn抑制剂##batoclimab#在#Graves病#和相关的#甲状腺眼病#(ted)的#首次临床研究#，#概念验证#POC就采用#随机对照试验#，看来研究真的太卷了！！这也提示#新药研发#的要求越来越高！！难度越来越大！

J Clin Endocrinol Metab：FcRN抑制剂BATOCLIMAB治疗甲状腺眼病的概念验证和随机安慰剂对照试验

2023-07-19发表于加利福尼亚

qidongfanjian (审核中...)

前往app查看评论内容

#甲状腺眼病#

2019美国甲状腺学会ATA：临床试验证实Teprotumumab可显着改善甲状腺眼病的眼胀、复视和炎症

2020-01-23

qidongfanjian (审核中...)

前往app查看评论内容

#甲状腺眼病#

2019年美国临床内分泌学家协会（AACE）大会：Teprotumumab治疗甲状腺眼病的III期试验结果

2019-05-24

qidongfanjian (审核中...)

前往app查看评论内容

#甲状腺眼病#

Horizon的teprotumumab治疗活动性甲状腺眼病III期临床试验大获成功

2019-06-27

qidongfanjian (审核中...)

前往app查看评论内容

#甲状腺眼病#

Ophthalmic Plast Reconstr Surg：上直肌-提肌复合体的增大对甲状腺眼病等压迫性视神经病变有显着贡献

2018-09-01

智者为医08 (审核中...)

前往app查看评论内容

#甲状腺眼病#

Ophthalmic Plast Reconstr Surg：从解剖学角度看甲状腺眼病

2018-07-08

智者为医08 (审核中...)

前往app查看评论内容

#甲状腺眼病#

Curr Opin Ophthalmol：甲状腺眼病的研究进展

2018-12-24

科室
- - 订阅+
  - 更多科室
工具
服务